SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The turnover for the March 2022 quarter moved up 65.04% to Rs. 5141.00 millions as compared to Rs. 3115.00 millions during the year-ago period.The Net Loss for the quarter ended March 2022 is Rs. -613.00 millions as compared to Net Profit of Rs. 572.00 millions of corresponding quarter ended March 2021Operating profit Margin for the quarter ended March 2022 slipped to -273.00% as compared to 1055.00% of corresponding quarter ended March 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 5141.00 3115.00 65.04 17678.00 16535.00 6.91 17678.00 16535.00 6.91
Other Income 104.00 291.00 -64.26 946.00 1011.00 -6.43 946.00 1011.00 -6.43
PBIDT -273.00 1055.00 -125.88 3076.00 5187.00 -40.70 3076.00 5187.00 -40.70
Interest 42.00 23.00 82.61 133.00 113.00 17.70 133.00 113.00 17.70
PBDT -315.00 1032.00 -130.52 2943.00 5074.00 -42.00 2943.00 5074.00 -42.00
Depreciation 356.00 298.00 19.46 1384.00 1152.00 20.14 1384.00 1152.00 20.14
PBT -671.00 734.00 -191.42 1559.00 3922.00 -60.25 1559.00 3922.00 -60.25
TAX -58.00 162.00 -135.80 168.00 827.00 -79.69 168.00 827.00 -79.69
Deferred Tax 14.00 -81.00 -117.28 -157.00 -106.00 48.11 -157.00 -106.00 48.11
PAT -613.00 572.00 -207.17 1391.00 3095.00 -55.06 1391.00 3095.00 -55.06
Equity 365.00 365.00 0.00 365.00 365.00 0.00 365.00 365.00 0.00
PBIDTM(%) -5.31 33.87 -115.68 17.40 31.37 -44.53 17.40 31.37 -44.53

Natco Pharma Share Price

1118.95 31.25 (2.87%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×